⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 3, 2024Open Access

Supplemental Table 3 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition

Martina Sarchi Courtnee Clough Edie I. Crosse Jason Kim Laura D. Baquero Galvis Nelli Aydinyan Rachel Wellington F. Yang Anna Gallì J. Philip Creamer Sintra Stewart Robert K. Bradley Luca Malcovati Sergei Doulatov

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Table 3. Drug screening of WT (Ctrl), SF3B1 K700E (S-A), SF3B1/RUNX1 (S-R), and SF3B1/STAG2 (S-S) K562 cells with the AML OncoPanel1 of 165 FDA-approved compounds.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sarchi et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db64358753396e https://doi.org/10.1158/2643-3230.26926126

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 3 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition2024
2Supplemental Table 2 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition2024
3Supplemental Table 2 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition2024
4Supplemental Table 1 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition2024
5Supplemental Table 1 from Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition2024